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Abstract: Cellular composition of bronchoalveolar lavage (BAL) fluid was compared
between two age-matched steroid-dependent intractable asthma (SOIA) groups: 17 group
A patients (serum IgG level < 1000mg/d£) whose immunity was regarded as being
suppressed by long-term glucocorticoid therapy and 17 group B patients (serum IgG
level> 1200mg/dQ). 1. The levels of serum IgA and IgM were significantly decreased
in group A compared to the levels in group B patients. 2. The number of blood
lymphocytes was also significantly lower in group A than in group B patients. However,
the number of blood neutrophils was not different between the two asthma groups. 3.
The number of BAL lymphocytes was significantly lower in group A than in group B
patients. 4. BAL neutrophilia (more than 1.5X10 4 /mQ) was observed in 6 of the 17
(35.3%) patients in group A, but not observed in any patients in group B. The number
of BAL neutrophils was significantly greater in group A than in group B patients.
These results suggest that there is a correlation between immunosuppression by
glucocorticoids and BAL neutrophilia in patients with bronchial asthma.
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Introduction
Recent studies on analysis of cellular and
humoral events in bronchoalveolar (BAL)
fluid have demonstrated that aIrway
inflammation is a common feature of bron-
chial asthma (1- 5). Airway inflammation
which consists of inflammatory cells such as
lymphocytes (6 - 8), neutrophils (9), eosin-
ophils (10, 11), and basophils, is related to
18 Immunosuppression and BAL neutrophilia in asthma
the severity of asthma (12).
Asthma is classified into three clinical
types according to symptoms and signs : Ia.
simple bronchoconstriction type, lb.
bronchoconstriction+hypersecretion type, and
II bronchiolar obstrution type (13 -15). Of
these three asthma types, type II asthma is
characterized by an increased number of
bronchoalveolar neutrophils and marked de-
crease in the values of ventilatory parame-
ters. An increased number of BAL neutrophils
is sometimes observed in asthmatic patients
with long-term glucocorticoid therapy (16).
These findings suggest that there is a correla-
tion between long-term glucocorticoid therapy
and an increased number of BAL neutrophils
in patients with bronchial asthma.
Long-term glucocorticoid regimen brings
about many side effects such as hypertension,
diabetes mellitus, osteoporosis, muscle weak-
ness, suppression of adrenocortical glands and
suppreSSIOn of humoral and cellular immu-
nity. Of these side effects, immuno-
suppression by glucocorticoids may affect
inflammatory process in the airways of
asthma and be related to asthma severity.
In the present study, a correlation between
immunosuppression by glucocorticoids and
BAL neutrophilia was examined in patients
with steroid-dependent intractable asthma
(SDIA).
Subjects and Methods
The subjects of this study were 34 patients
with bronchial asthma (17 females and 17
males, mean 53.0 years, range 21-71 years).
The mean level of serum IgE was 428 IV/'mR
(range 11- 3058 IV/mR). All the subjects
were non-smokers, and they were regarded as
having steroid-dependent intractable asthma
(SDIA), since they had been treated with
glucocorticoids for more than 2 years. The
subjects were divided into two groups accord-
ing to the level of serum IgG : less than 1000
mg/d1! (group A) and more than 1200 mg/
d1! (group B). The patients in group A were
regarded as their immunity being suppressed
by glucocorticoids, and in group B patients
the immunity was not suppressed.
Bronchoalveolar lavage (BAL) was per-
formed after informed consent was obtained
from all the subjects. The BAL was carried
out in all study subjects by a previously
reported method (14, 15) when their attacks
were atable with prednisolone of 5 mg/day or
less. Briefly, the aspirates were centrifuged
at 1200 rpm for 10 min at 4°C after filtra-
tion though a sterile steel mesh, and the
resultant cell pellet was resuspended in Tris
ACM. After total cell number was counted,
smear praparations made with the cell sus-
pensions were stained with May Giemsa. A
differential cell count was performed on 500
cells, excluding epithelial cells. In the present
study, the mean recovery rate at BAL was 2
6.5±11.4% (±SD), and the total cell number
was 7.0±3.0X10 6 • The results were expressed
as /m1!.
The levels of serum IgG, IgA, and IgM were
measured by turbidometric Immunoassay.
Serum IgE level was estimated by
radioimmunosorbest test (RIST).
Results
Table 1 shows characteristics of patients
with bronchial asthma divided by the level of
serum IgG. In this study, 17 patients whose
immunity was suppressed by long-term
glucocorticoid therapy were at first selected,
and then 17 age-matched asthma patients
whose serum IgG level was more than 1200
mg/d1! (regarded as not being suppressed by
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glucocorticoids) were selected. Thus, the
mean age in the two groups was almost
same. Serum IgE level was higher in patients
of group B than in those of group A, al-
though this difference was not significant.
The levels of serum IgA and IgM were signifi-
cantly lower in patients of group A than in
those of group B (IgA : p<0.02 ; IgM :
p<O.Ol). Distribution of serum IgG levels III
groups A and B was shown in Fig. 1.
Table 1. Characteristics of patients with
bronchial asthma studied
Serum levels of
Asthma No of Age
* ** ** **group patients (yrl IgE IgG IgA IgM
A 17 52.9 306 873 194a 136b
±356 ±118 ± 65 ±104
B 17 53.1 531 1402 246a 224b
±733 ±195 ± 53 ± 67
Group A: patients with serum IgG level of less than
mg/dl; B: patients with serum IgG level of less than
1200 mg/dl. *IU/ml. **mg/dl. a:p <0.02: b: p( 0.01.
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Fig. 1. Serum IgG levels in patients with
bronchial asthma. Group A : patients
with serum IgG level of less than
1000 mg/dI! ; B : patients with serum
IgG levels of more than 1200 mg/dI!.
Immunosuppressive action of glucocorticoids
can be observed in serum immunoglobulin
concentrations and blood cell count in periph-
eral blood. The number of blood neutrophils
was not different between groups A (4808 ± 1
286/cmm) and B (4576 ± 1419/cmm), as
shown in Fig. 2. The number of blood lym-
phocytes was significantly decreased in group
A patients (serum IgG level less than 1000
mg/dI!) compared to that in group B patients
(p<O.Ol) (Fig. 3).
Table 2 shows the results of BAL examina-
tions. Total cell number and recovery rate at
BAL were slightly greater in group B than in
group A subjects, although this was not
significant.
The number of BAL macrophages was not
significantly diffirent between groups A and
B (FIg. 4). The number of BAL lymphocytes
was decreased in group A patients, which was
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Fig. 2. Number of blood neutrophils III
patients with bronchial asthma.
Group A : patients with serum IgG
level of less than 1000 mg/ dI! ; B :
patients with serum IgG level of
more than 1200 mg/dI!.
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significantly lower than that in group B
patients (P<0.05) (Fig. 5). BAL neutrophillia
(more than 1.5 X 10 4 / me) was observed in 6
of the 17 (35.3%) patients in group A, but in
none of them in group B. The mean number
of BAL neutrophils was significantly greater
III group A than III group B patients
(p<0.05) (Fig. 6, Table 2).
Fig. 4. Number of BAL macrophages III
patients with bronchial asthma.
Group A : patients with serum IgG
level of less than 1000 mg/dP ; group
B : patients with serum IgG level of
more than 1200 mg/dP.
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Fig. 3. Number of blood lymphocytes In
patients with bronchial asthma.
Group A : patients with serum IgG
level of less than 1000 mg/dP ; group
B : patients with serum IgG level of
more than 1200 mg/dP. 'p < 0.01.
Table 2. BAL examination results in. patients
with bronchial asthma studied
Asthma Recovery Total c~~~05) BAL cells (104 /mllgroup rate number Mac Lym Neut EOB
Fig. 5.
A 24.7 6.2 11.8 1.24a 3.44b 3.5
±10.1 ±2.B ±12.2 .1.18 ±5.7 ±5.1
B 28.4 7.7 14.5 3.13n 0.35b 1.55
±12.2 ±3.1 ± 6.4 ±1.56 ±0.31 ±2.55
Group A: patients with serum IgG level of less than 1000 mq/dl;
B: patients with serum IqG level of more than 1200 mq/dl.,
Mac, macrophages; L~. lymphocytes; Neut. neutrophils; Eas,
eosinophils. a:p (0.001: b:p (0.05.
""e
-... 8
...
0
"
•
..
QJ
...,
><
u
0 5 -
•.c •
'" I~
""
•••
~ .... *
• ••
""
., .:0
• •~
..... *QJ •••.Q
e
~
z 0
Group A Group B
Number of BAL lymphocytes III pa
tients with bronchial asthma. Group
A : patients with serum IgG level of
less than 1000 mg / dP ; group B:
patients with serum IgG level of
more than 1200 mg/dP. 'p < 0.001.
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Despite many kinds of newly developed
antiasthma agents, there are some patients
with bronchial asthma whose aatcks can not
be controlled with conventinal antiasthma
drugs except glucocorticoids. They often
require long-term glucocorticoid therapy to
control asthma attacks. Long-term glucocor-
ticoid therapy for bronchial asthma brings
about many side effects. Of these side ef-
fects, suppression of adrenocortical glands
and suppressed immunity by glucocorticoids
may affect the pathogenesis of asthma.
There is increasing evidence that airway
inflammation in bronchial asthma play an
important role in the pathogenesis of the
disease (1-5). The roles of inflammatory
cells such as lymphocytes (6-8), neutrophils
-*
(9), eosinophils (10, 11), and basophils,
which migrate from bloodstream, have been
extensively studied in patients with asthma.
It has been reported that numbers of acti-
vated T-lymphocytes and eosinophils in BAL
fluid are increased in asthma attacks com-
pared to healthy subjects (12). Long-term
glucocorticoid therapy may affect these in-
flammatory cells in patients with asthma.
In the present study, cellular composition
of bronchoalveolar lavage (BAL) fluid was
examined in relation to suppressed immunity
by glucocorticoids. Two asthma groups,
group A whose immunity was suppressed by
glucocorticoids, as expressed by low serum
IgG level (less than 1000 mg/d1!), and group
B whose immunity was not suppressed, con-
sisted of each 17 patient group with steroid-
dependent intractable asthma (SDIA). In
group A patients (with suppressed immu-
nity), decreased levels of IgG, IgA, and IgM,
and decreased numbers of blood and BAL
lymphocytes were observed compared to the
numbers in group B patients (without sup-
pressed immunity). These results show that
serum levels of immunoglobulins, IgG, IgA,
and IgM, and numbers of blood and BAL
lymphocytes tend to decrease in some pa-
tients with asthma by long-term glucocor-
ticoid therapy.
BAL neutrophilia (more than 1.5X10·/mf)
was observed in, 6 of the 17 (35.3%) patients
with suppressed immunity, but in none of
them without suppressed immunity. Moreo-
ver, the number of BAL neutrophils was
significantly greater in group A than in
group B patients. The results suggest that
long-term glucocorticoid therapy brings about
suppressed immunity as expressed by de-
creased levels of serum IgG, IgA, and IgM,
and decreased numbers of blood and BAL
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Number of BAL neutrophils III pa
tients with bronchial asthma. Group
A : patients with serum IgG level of
less than 1000 mg / d1! ; group B :
patients with serum IgG level of
more than 1200 mg/d1!. 'p < 0.05.
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lymphocytes, and in such patients with sup-
pressed immunity BAL neutrophilia is often
observed. In these conditions, asthma is
severe and difficult to control.
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気管支瑞息における副腎皮質ホルモン長期投与に
よる免疫抑制と気管支肺胞洗浄液中好中球増多と
の関連
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ステロイド依存性重症難治性噂息を,免疫抑制
の見られる症例 (血清IgG値 10007岬/dP以下)
(グループA)と抑制の見られない症例 (血清
IgG値 1200mg/dP以上)(グループB)の2群
に分け,気管支肺胞洗浄液中の細胞成分について
比較検討した｡
1.血清IgAおよびIgM値は,グループBに比べ
免疫抑制の見られるグループAにおいて有意に
低い値であった｡
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16. TanizakiY,Kitani H, Okazaki M,
MifuneT,MitsunobuF,KimuraI:Effects
of long-term glucocortiocid therapy on
bronchoalveolarcellsinadultpatientswith
bronchialasthma.JAsthma30:257-262,
1993.
2.末梢血リンパ球数は,グループAにおいて,
グループBに比べ有意に少ない傾向が見られた｡
しかし,末梢血好中球数は両群間に有意の差は
見られなかった｡
3.BAL液中リンパ球数は,グループBに比べ免
疫抑制の見られるグループAにおいて有意に少
ない数であった｡
4.BAI.液中好中球増多 (1.5×104/mA以上)
を示す症例は, グループAの17例中 6例
(35.3%)に見られたが,グループBでは全く
見られなかった｡また,BAL液中好中球数は,
グループAにおいてグループBに比べ有意に多
い数であった｡
以上の結果により,副腎皮質ホルモン長期投与
による免疫抑制とBAL液中好中球増多とはある
程度関連があることが明らかにされた｡
キーワード:免疫抑制,BAL好中球増多,副腎
皮質ホルモン,気管支喋息
